What the FDA labels say about taking them together
Atazanavir and clopidogrel
Atazanavir's FDA label of August 6, 2025 names clopidogrel in its drug interactions section; the clopidogrel label PlainMeds reads does not name atazanavir. The atazanavir label: “Coadministration of REYATAZ and clopidogrel is not recommended. This is due to the potential reduction of the antiplatelet activity of clopidogrel.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC).
What does the atazanavir label say about clopidogrel?
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Antiplatelets ticagrelor clopidogrel; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ ticagrelor ↓ clopidogrel active metabolite; Clinical Comment: Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. Coadministration of atazanavir (with or without ritonavir) and clopidogrel is not recommended. This is due to the potential reduction of the antiplatelet activity of clopidogrel.
Reyataz label (E.R. Squibb & Sons, L.L.C., December 5, 2024), drug interactionsConcomitant Drug Class/Specific Drugs: clopidogrel; Effect on Concentration of Atazanavir or Concomitant Drug: ↓ clopidogrel active metabolite; Clinical Comment: Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. This is due to the potential reduction of the antiplatelet activity of clopidogrel.
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the clopidogrel label say about atazanavir?
Clopidogrel's label (effective May 30, 2025) does not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Clopidogrel | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, Angina |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.0472 per tablet 75 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once